Cowen and Company restated their hold rating on shares of ImmunoGen, Inc. (NASDAQ:IMGN) in a research note issued to investors on Tuesday.

“IMGN announced a collaboration agreement with Jazz for the development and.”,” the firm’s analyst commented.

A number of other equities research analysts have also weighed in on IMGN. Canaccord Genuity set a $6.00 target price on shares of ImmunoGen and gave the stock a buy rating in a report on Saturday, May 6th. Royal Bank Of Canada set a $5.00 target price on shares of ImmunoGen and gave the stock a hold rating in a report on Saturday, May 6th. BidaskClub raised shares of ImmunoGen from a hold rating to a buy rating in a report on Saturday. Cantor Fitzgerald reissued a hold rating on shares of ImmunoGen in a report on Tuesday. Finally, Jefferies Group LLC reissued a buy rating and set a $9.00 target price on shares of ImmunoGen in a report on Monday, August 7th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the stock. ImmunoGen presently has a consensus rating of Hold and an average target price of $7.72.

Shares of ImmunoGen (IMGN) opened at 7.58 on Tuesday. The company’s market cap is $679.15 million. The company’s 50-day moving average price is $6.23 and its 200 day moving average price is $4.69. ImmunoGen has a one year low of $1.51 and a one year high of $8.04.

ImmunoGen (NASDAQ:IMGN) last posted its earnings results on Friday, July 28th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.07. The business had revenue of $39.02 million for the quarter, compared to the consensus estimate of $30.59 million. During the same period in the previous year, the firm earned ($0.53) earnings per share. The company’s revenue was up 426.6% compared to the same quarter last year. Equities analysts forecast that ImmunoGen will post ($0.74) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “ImmunoGen, Inc. (IMGN) Receives Hold Rating from Cowen and Company” was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/immunogen-inc-imgn-receives-hold-rating-from-cowen-and-company/1531458.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMGN. JPMorgan Chase & Co. increased its position in ImmunoGen by 37,346.0% in the first quarter. JPMorgan Chase & Co. now owns 187,230 shares of the biotechnology company’s stock worth $725,000 after buying an additional 186,730 shares during the last quarter. Envestnet Asset Management Inc. increased its position in ImmunoGen by 2.8% in the first quarter. Envestnet Asset Management Inc. now owns 27,761 shares of the biotechnology company’s stock worth $107,000 after buying an additional 743 shares during the last quarter. Parametric Portfolio Associates LLC increased its position in ImmunoGen by 7.7% in the first quarter. Parametric Portfolio Associates LLC now owns 38,492 shares of the biotechnology company’s stock worth $149,000 after buying an additional 2,753 shares during the last quarter. Ameriprise Financial Inc. bought a new position in ImmunoGen during the first quarter worth about $1,528,000. Finally, UBS Asset Management Americas Inc. increased its position in ImmunoGen by 148.6% in the first quarter. UBS Asset Management Americas Inc. now owns 68,097 shares of the biotechnology company’s stock worth $264,000 after buying an additional 40,700 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

ImmunoGen Company Profile

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Analyst Recommendations for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.